Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Selling SAGE Therapeutics Inc (SAGE)

Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the big brokerage houses don’t follow. Small caps are where they can generate significant out-performance. That’s why we pay special attention to hedge fund activity in these stocks.

SAGE Therapeutics Inc (NASDAQ:SAGE) was in 17 hedge funds’ portfolios at the end of the third quarter of 2015. SAGE shareholders have witnessed a decrease in support from the world’s most elite money managers lately. There were 21 hedge funds in our database with SAGE positions at the end of the previous quarter. At the end of this article we will also compare SAGE to other stocks including Itron, Inc. (NASDAQ:ITRI), ExlService Holdings, Inc. (NASDAQ:EXLS), and Oasis Petroleum Inc. (NYSE:OAS) to get a better sense of its popularity.

Follow Sage Therapeutics Inc. (NASDAQ:SAGE)
Trade (NASDAQ:SAGE) Now!

In the eyes of most shareholders, hedge funds are viewed as unimportant, outdated financial tools of years past. While there are more than 8000 funds trading at the moment, Our researchers choose to focus on the aristocrats of this club, approximately 700 funds. These investment experts watch over bulk of the smart money’s total capital, and by keeping an eye on their matchless equity investments, Insider Monkey has unearthed a number of investment strategies that have historically outstripped Mr. Market. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points a year for a decade in their back tests.

Keeping this in mind, let’s take a look at the latest action regarding SAGE Therapeutics Inc (NASDAQ:SAGE).

How are hedge funds trading SAGE Therapeutics Inc (NASDAQ:SAGE)?

At the end of the third quarter, a total of 17 of the hedge funds tracked by Insider Monkey held long positions in this stock, a drop of 19% from the previous quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were upping their stakes substantially (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Jeremy Green’s Redmile Group has the biggest position in SAGE Therapeutics Inc (NASDAQ:SAGE), worth close to $626 million, amounting to 14.4% of its total 13F portfolio. The second largest stake is held by Visium Asset Management, led by Jacob Gottlieb, holding a $38.2 million position; 0.5% of its 13F portfolio is allocated to the stock. Other members of the smart money that are bullish encompass James E. Flynn’s Deerfield Management, Sanford J. Colen’s Apex Capital and Bihua Chen’s Cormorant Asset Management.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.